Jyseleca ® (filgotinib) has received expanded approval for the treatment of patients with active axial...
Advocates are sounding the alarm on social media as they learn from their doctors that...
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:...
Design of Phase 3 INTREPID study of sapablursen in polycythemia vera to be presented at...
Q3 2026 results: Net sales of $548 million rise 3% and also 3% at...
New fixed, single-room configuration is designed to make DeepOCT+NIRS Imaging and X1-FFR physiology readily available...
Four presentations highlight BriaCell’s Bria-OTS+™ cellular immunotherapy platform and BriaPro’s CD80-based immunotherapy programs In vitro...
High-performance hydrophilic coatings bond directly to metal surfaces without primers or tie-coats, simplifying manufacturing and...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG),...
The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991). 1 AIRWARD will evaluate...
Since Pfizer already owns a tick-borne encephalitis franchise in Europe, the region is a natural...
Canada is among the first internationally recognized HTA bodies to issue a positive reimbursement recommendation...
AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small...
With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’...
AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William...